Thioredoxin reductase as a novel biomarker for the diagnosis and efficacy prediction of gastrointestinal malignancy: a large-scale, retrospective study
Background Our aim was to investigate the rationality and accuracy of plasma TrxR activity as an efficient tool in the early diagnosis of gastrointestinal malignancy, and whether TrxR can be used to evaluate the therapeutic efficacy of gastrointestinal malignancy. Methods We enrolled a total of 5091...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2023-07, Vol.28 (7), p.880-892 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 892 |
|---|---|
| container_issue | 7 |
| container_start_page | 880 |
| container_title | International journal of clinical oncology |
| container_volume | 28 |
| creator | Hu, Yixuan Zhu, Yinxing Nie, Weiwei Shi, Junfeng Wei, Xiaowei Tang, Cuiju Zhang, Wenwen |
| description | Background
Our aim was to investigate the rationality and accuracy of plasma TrxR activity as an efficient tool in the early diagnosis of gastrointestinal malignancy, and whether TrxR can be used to evaluate the therapeutic efficacy of gastrointestinal malignancy.
Methods
We enrolled a total of 5091 cases, including 3736 cases in gastrointestinal malignancy, 964 in benign diseases, and 391 cases in healthy controls. We also performed receiver operating characteristic (ROC) analysis to evaluate diagnostic efficiency of TrxR. Finally, we detected pre- and post-treatment level of TrxR and common tumor markers.
Results
The plasma TrxR level in patients with gastrointestinal malignancy [8.4 (6.9, 9.7) U/mL] was higher than that in patients with benign disease [5.8 (4.6, 6.9) U/mL] and healthy control [3.5 (1.4, 5.4) U/mL]. Plasma TrxR showed a significant diagnostic advantage with an AUC of 0.897, compared with conventional tumor markers. In addition, the combination of TrxR and conventional tumor markers can further improve the diagnostic efficiency. We derived the optimal cut-off value of plasma TrxR as a diagnostic marker of gastrointestinal malignancy according to Youden index of 6.15 U/mL. After measuring the change trend of TrxR activity and conventional tumor markers before and after anti-tumor treatments, we found that their change trend was generally consistent, and the plasma TrxR activity was significantly decreased in patients treated with chemotherapy, targeted therapy and immunotherapy.
Conclusions
Our findings recommend that plasma TrxR activity could be monitored as an efficient tool for the early diagnosis of gastrointestinal malignancy and as a feasible tool to evaluate the therapeutic effect. |
| doi_str_mv | 10.1007/s10147-023-02350-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2810916674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890336088</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-6b5e9088580cff18c0b65a57ef5f82864398728d0f1437c46468934f1f565f913</originalsourceid><addsrcrecordid>eNp9kctuFDEQRVsIRELgB1ggS2xY0OD3gx2KeEmR2IR1y-Mudxx67MHuTpgv4XepYQJILFhYZcnn3qry7bqnjL5ilJrXjVEmTU-5OBxF-9t73SmTwvTGGH4f70Ky3mmuTrpHrV1TyoxW_GF3IgyT3Fp22v24vEqlwli-p0ywrmHxDYhvxJNcbmAmm1S2vn6FSmKpZLkCMiY_5dISMnkkEGMKPuzJDuUpLKlkUiKZfFtqSXmBtqTsZ7L1c5qyz2H_Br1nXyfoW_AzvMS-iLYdoPgGSFvWcf-4exD93ODJXT3rvrx_d3n-sb_4_OHT-duLPgjnll5vFDhqrbI0xMhsoButvDIQVbTcaimcNdyONB7-JUgttXVCRhaVVtExcda9OPruavm24qzDNrUA8-wzlLUN3DLqmNZGIvr8H_S6rBVXO1COCqFxEKT4kQq4UqsQh11N-IH7gdHhENtwjG3AyIZfsQ23KHp2Z71utjD-kfzOCQFxBBo-5Qnq397_sf0JiG-lLw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890336088</pqid></control><display><type>article</type><title>Thioredoxin reductase as a novel biomarker for the diagnosis and efficacy prediction of gastrointestinal malignancy: a large-scale, retrospective study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hu, Yixuan ; Zhu, Yinxing ; Nie, Weiwei ; Shi, Junfeng ; Wei, Xiaowei ; Tang, Cuiju ; Zhang, Wenwen</creator><creatorcontrib>Hu, Yixuan ; Zhu, Yinxing ; Nie, Weiwei ; Shi, Junfeng ; Wei, Xiaowei ; Tang, Cuiju ; Zhang, Wenwen</creatorcontrib><description>Background
Our aim was to investigate the rationality and accuracy of plasma TrxR activity as an efficient tool in the early diagnosis of gastrointestinal malignancy, and whether TrxR can be used to evaluate the therapeutic efficacy of gastrointestinal malignancy.
Methods
We enrolled a total of 5091 cases, including 3736 cases in gastrointestinal malignancy, 964 in benign diseases, and 391 cases in healthy controls. We also performed receiver operating characteristic (ROC) analysis to evaluate diagnostic efficiency of TrxR. Finally, we detected pre- and post-treatment level of TrxR and common tumor markers.
Results
The plasma TrxR level in patients with gastrointestinal malignancy [8.4 (6.9, 9.7) U/mL] was higher than that in patients with benign disease [5.8 (4.6, 6.9) U/mL] and healthy control [3.5 (1.4, 5.4) U/mL]. Plasma TrxR showed a significant diagnostic advantage with an AUC of 0.897, compared with conventional tumor markers. In addition, the combination of TrxR and conventional tumor markers can further improve the diagnostic efficiency. We derived the optimal cut-off value of plasma TrxR as a diagnostic marker of gastrointestinal malignancy according to Youden index of 6.15 U/mL. After measuring the change trend of TrxR activity and conventional tumor markers before and after anti-tumor treatments, we found that their change trend was generally consistent, and the plasma TrxR activity was significantly decreased in patients treated with chemotherapy, targeted therapy and immunotherapy.
Conclusions
Our findings recommend that plasma TrxR activity could be monitored as an efficient tool for the early diagnosis of gastrointestinal malignancy and as a feasible tool to evaluate the therapeutic effect.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-023-02350-w</identifier><identifier>PMID: 37142881</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Biomarkers ; Biomarkers, Tumor ; Cancer Research ; Chemotherapy ; Diagnosis ; Gastrointestinal Neoplasms - diagnosis ; Gastrointestinal Neoplasms - drug therapy ; Humans ; Immunotherapy ; Malignancy ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Plasma ; Retrospective Studies ; Surgical Oncology ; Thioredoxin ; Thioredoxin-Disulfide Reductase ; Tumor markers ; Tumors</subject><ispartof>International journal of clinical oncology, 2023-07, Vol.28 (7), p.880-892</ispartof><rights>The Author(s) under exclusive licence to Japan Society of Clinical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-6b5e9088580cff18c0b65a57ef5f82864398728d0f1437c46468934f1f565f913</citedby><cites>FETCH-LOGICAL-c399t-6b5e9088580cff18c0b65a57ef5f82864398728d0f1437c46468934f1f565f913</cites><orcidid>0000-0003-1285-3118</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-023-02350-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-023-02350-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37142881$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Yixuan</creatorcontrib><creatorcontrib>Zhu, Yinxing</creatorcontrib><creatorcontrib>Nie, Weiwei</creatorcontrib><creatorcontrib>Shi, Junfeng</creatorcontrib><creatorcontrib>Wei, Xiaowei</creatorcontrib><creatorcontrib>Tang, Cuiju</creatorcontrib><creatorcontrib>Zhang, Wenwen</creatorcontrib><title>Thioredoxin reductase as a novel biomarker for the diagnosis and efficacy prediction of gastrointestinal malignancy: a large-scale, retrospective study</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
Our aim was to investigate the rationality and accuracy of plasma TrxR activity as an efficient tool in the early diagnosis of gastrointestinal malignancy, and whether TrxR can be used to evaluate the therapeutic efficacy of gastrointestinal malignancy.
Methods
We enrolled a total of 5091 cases, including 3736 cases in gastrointestinal malignancy, 964 in benign diseases, and 391 cases in healthy controls. We also performed receiver operating characteristic (ROC) analysis to evaluate diagnostic efficiency of TrxR. Finally, we detected pre- and post-treatment level of TrxR and common tumor markers.
Results
The plasma TrxR level in patients with gastrointestinal malignancy [8.4 (6.9, 9.7) U/mL] was higher than that in patients with benign disease [5.8 (4.6, 6.9) U/mL] and healthy control [3.5 (1.4, 5.4) U/mL]. Plasma TrxR showed a significant diagnostic advantage with an AUC of 0.897, compared with conventional tumor markers. In addition, the combination of TrxR and conventional tumor markers can further improve the diagnostic efficiency. We derived the optimal cut-off value of plasma TrxR as a diagnostic marker of gastrointestinal malignancy according to Youden index of 6.15 U/mL. After measuring the change trend of TrxR activity and conventional tumor markers before and after anti-tumor treatments, we found that their change trend was generally consistent, and the plasma TrxR activity was significantly decreased in patients treated with chemotherapy, targeted therapy and immunotherapy.
Conclusions
Our findings recommend that plasma TrxR activity could be monitored as an efficient tool for the early diagnosis of gastrointestinal malignancy and as a feasible tool to evaluate the therapeutic effect.</description><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Gastrointestinal Neoplasms - diagnosis</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Malignancy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Plasma</subject><subject>Retrospective Studies</subject><subject>Surgical Oncology</subject><subject>Thioredoxin</subject><subject>Thioredoxin-Disulfide Reductase</subject><subject>Tumor markers</subject><subject>Tumors</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kctuFDEQRVsIRELgB1ggS2xY0OD3gx2KeEmR2IR1y-Mudxx67MHuTpgv4XepYQJILFhYZcnn3qry7bqnjL5ilJrXjVEmTU-5OBxF-9t73SmTwvTGGH4f70Ky3mmuTrpHrV1TyoxW_GF3IgyT3Fp22v24vEqlwli-p0ywrmHxDYhvxJNcbmAmm1S2vn6FSmKpZLkCMiY_5dISMnkkEGMKPuzJDuUpLKlkUiKZfFtqSXmBtqTsZ7L1c5qyz2H_Br1nXyfoW_AzvMS-iLYdoPgGSFvWcf-4exD93ODJXT3rvrx_d3n-sb_4_OHT-duLPgjnll5vFDhqrbI0xMhsoButvDIQVbTcaimcNdyONB7-JUgttXVCRhaVVtExcda9OPruavm24qzDNrUA8-wzlLUN3DLqmNZGIvr8H_S6rBVXO1COCqFxEKT4kQq4UqsQh11N-IH7gdHhENtwjG3AyIZfsQ23KHp2Z71utjD-kfzOCQFxBBo-5Qnq397_sf0JiG-lLw</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Hu, Yixuan</creator><creator>Zhu, Yinxing</creator><creator>Nie, Weiwei</creator><creator>Shi, Junfeng</creator><creator>Wei, Xiaowei</creator><creator>Tang, Cuiju</creator><creator>Zhang, Wenwen</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1285-3118</orcidid></search><sort><creationdate>20230701</creationdate><title>Thioredoxin reductase as a novel biomarker for the diagnosis and efficacy prediction of gastrointestinal malignancy: a large-scale, retrospective study</title><author>Hu, Yixuan ; Zhu, Yinxing ; Nie, Weiwei ; Shi, Junfeng ; Wei, Xiaowei ; Tang, Cuiju ; Zhang, Wenwen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-6b5e9088580cff18c0b65a57ef5f82864398728d0f1437c46468934f1f565f913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Gastrointestinal Neoplasms - diagnosis</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Malignancy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Plasma</topic><topic>Retrospective Studies</topic><topic>Surgical Oncology</topic><topic>Thioredoxin</topic><topic>Thioredoxin-Disulfide Reductase</topic><topic>Tumor markers</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Yixuan</creatorcontrib><creatorcontrib>Zhu, Yinxing</creatorcontrib><creatorcontrib>Nie, Weiwei</creatorcontrib><creatorcontrib>Shi, Junfeng</creatorcontrib><creatorcontrib>Wei, Xiaowei</creatorcontrib><creatorcontrib>Tang, Cuiju</creatorcontrib><creatorcontrib>Zhang, Wenwen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Yixuan</au><au>Zhu, Yinxing</au><au>Nie, Weiwei</au><au>Shi, Junfeng</au><au>Wei, Xiaowei</au><au>Tang, Cuiju</au><au>Zhang, Wenwen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thioredoxin reductase as a novel biomarker for the diagnosis and efficacy prediction of gastrointestinal malignancy: a large-scale, retrospective study</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>28</volume><issue>7</issue><spage>880</spage><epage>892</epage><pages>880-892</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
Our aim was to investigate the rationality and accuracy of plasma TrxR activity as an efficient tool in the early diagnosis of gastrointestinal malignancy, and whether TrxR can be used to evaluate the therapeutic efficacy of gastrointestinal malignancy.
Methods
We enrolled a total of 5091 cases, including 3736 cases in gastrointestinal malignancy, 964 in benign diseases, and 391 cases in healthy controls. We also performed receiver operating characteristic (ROC) analysis to evaluate diagnostic efficiency of TrxR. Finally, we detected pre- and post-treatment level of TrxR and common tumor markers.
Results
The plasma TrxR level in patients with gastrointestinal malignancy [8.4 (6.9, 9.7) U/mL] was higher than that in patients with benign disease [5.8 (4.6, 6.9) U/mL] and healthy control [3.5 (1.4, 5.4) U/mL]. Plasma TrxR showed a significant diagnostic advantage with an AUC of 0.897, compared with conventional tumor markers. In addition, the combination of TrxR and conventional tumor markers can further improve the diagnostic efficiency. We derived the optimal cut-off value of plasma TrxR as a diagnostic marker of gastrointestinal malignancy according to Youden index of 6.15 U/mL. After measuring the change trend of TrxR activity and conventional tumor markers before and after anti-tumor treatments, we found that their change trend was generally consistent, and the plasma TrxR activity was significantly decreased in patients treated with chemotherapy, targeted therapy and immunotherapy.
Conclusions
Our findings recommend that plasma TrxR activity could be monitored as an efficient tool for the early diagnosis of gastrointestinal malignancy and as a feasible tool to evaluate the therapeutic effect.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>37142881</pmid><doi>10.1007/s10147-023-02350-w</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-1285-3118</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2023-07, Vol.28 (7), p.880-892 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2810916674 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Biomarkers Biomarkers, Tumor Cancer Research Chemotherapy Diagnosis Gastrointestinal Neoplasms - diagnosis Gastrointestinal Neoplasms - drug therapy Humans Immunotherapy Malignancy Medicine Medicine & Public Health Oncology Original Article Plasma Retrospective Studies Surgical Oncology Thioredoxin Thioredoxin-Disulfide Reductase Tumor markers Tumors |
| title | Thioredoxin reductase as a novel biomarker for the diagnosis and efficacy prediction of gastrointestinal malignancy: a large-scale, retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T21%3A32%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thioredoxin%20reductase%20as%20a%20novel%20biomarker%20for%20the%20diagnosis%20and%20efficacy%20prediction%20of%20gastrointestinal%20malignancy:%20a%20large-scale,%20retrospective%20study&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Hu,%20Yixuan&rft.date=2023-07-01&rft.volume=28&rft.issue=7&rft.spage=880&rft.epage=892&rft.pages=880-892&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-023-02350-w&rft_dat=%3Cproquest_cross%3E2890336088%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890336088&rft_id=info:pmid/37142881&rfr_iscdi=true |